Impact and effectiveness of the quadrivalent human papillomavirus vaccine

A systematic review of 10 years of real-world experience

Suzanne M. Garland, Susanne K. Kjaer, Nubia Muñoz, Stan L. Block, Darron Brown, Mark J. Dinubile, Brianna R. Lindsay, Barbara J. Kuter, Gonzalo Perez, Geraldine Dominiak-Felden, Alfred J. Saah, Rosybel Drury, Rituparna Das, Christine Velicer

Research output: Contribution to journalReview article

156 Citations (Scopus)

Abstract

Prophylactic human papillomavirus (HPV) vaccination programs constitute major public health initiatives worldwide. We assessed the global effect of quadrivalent HPV (4vHPV) vaccination on HPV infection and disease. PubMed and Embase were systematically searched for peer-reviewed articles from January 2007 through February 2016 to identify observational studies reporting the impact or effectiveness of 4vHPV vaccination on infection, anogenital warts, and cervical cancer or precancerous lesions. Over the last decade, the impact of HPV vaccination in real-world settings has become increasingly evident, especially among girls vaccinated before HPV exposure in countries with high vaccine uptake. Maximal reductions of approximately 90% for HPV 6/11/16/18 infection, approximately 90% for genital warts, approximately 45% for low-grade cytological cervical abnormalities, and approximately 85% for high-grade histologically proven cervical abnormalities have been reported. The full public health potential of HPV vaccination is not yet realized. HPV-related disease remains a significant source of morbidity and mortality in developing and developed nations, underscoring the need for HPV vaccination programs with high population coverage.

Original languageEnglish (US)
Pages (from-to)519-527
Number of pages9
JournalClinical Infectious Diseases
Volume63
Issue number4
DOIs
StatePublished - Aug 15 2016

Fingerprint

Papillomavirus Vaccines
Vaccination
Public Health
Human papillomavirus 11
Human papillomavirus 6
Condylomata Acuminata
Warts
Papillomavirus Infections
Infection
Developed Countries
PubMed
Uterine Cervical Neoplasms
Developing Countries
Observational Studies
Vaccines
Morbidity
Mortality

Keywords

  • Cervical cancer
  • CIN
  • Gardasil/Silgard
  • Genital warts
  • HPV vaccination

ASJC Scopus subject areas

  • Medicine(all)
  • Microbiology (medical)
  • Infectious Diseases

Cite this

Impact and effectiveness of the quadrivalent human papillomavirus vaccine : A systematic review of 10 years of real-world experience. / Garland, Suzanne M.; Kjaer, Susanne K.; Muñoz, Nubia; Block, Stan L.; Brown, Darron; Dinubile, Mark J.; Lindsay, Brianna R.; Kuter, Barbara J.; Perez, Gonzalo; Dominiak-Felden, Geraldine; Saah, Alfred J.; Drury, Rosybel; Das, Rituparna; Velicer, Christine.

In: Clinical Infectious Diseases, Vol. 63, No. 4, 15.08.2016, p. 519-527.

Research output: Contribution to journalReview article

Garland, SM, Kjaer, SK, Muñoz, N, Block, SL, Brown, D, Dinubile, MJ, Lindsay, BR, Kuter, BJ, Perez, G, Dominiak-Felden, G, Saah, AJ, Drury, R, Das, R & Velicer, C 2016, 'Impact and effectiveness of the quadrivalent human papillomavirus vaccine: A systematic review of 10 years of real-world experience', Clinical Infectious Diseases, vol. 63, no. 4, pp. 519-527. https://doi.org/10.1093/cid/ciw354
Garland, Suzanne M. ; Kjaer, Susanne K. ; Muñoz, Nubia ; Block, Stan L. ; Brown, Darron ; Dinubile, Mark J. ; Lindsay, Brianna R. ; Kuter, Barbara J. ; Perez, Gonzalo ; Dominiak-Felden, Geraldine ; Saah, Alfred J. ; Drury, Rosybel ; Das, Rituparna ; Velicer, Christine. / Impact and effectiveness of the quadrivalent human papillomavirus vaccine : A systematic review of 10 years of real-world experience. In: Clinical Infectious Diseases. 2016 ; Vol. 63, No. 4. pp. 519-527.
@article{941cc9aa5e6545248253f61ed59d88e3,
title = "Impact and effectiveness of the quadrivalent human papillomavirus vaccine: A systematic review of 10 years of real-world experience",
abstract = "Prophylactic human papillomavirus (HPV) vaccination programs constitute major public health initiatives worldwide. We assessed the global effect of quadrivalent HPV (4vHPV) vaccination on HPV infection and disease. PubMed and Embase were systematically searched for peer-reviewed articles from January 2007 through February 2016 to identify observational studies reporting the impact or effectiveness of 4vHPV vaccination on infection, anogenital warts, and cervical cancer or precancerous lesions. Over the last decade, the impact of HPV vaccination in real-world settings has become increasingly evident, especially among girls vaccinated before HPV exposure in countries with high vaccine uptake. Maximal reductions of approximately 90{\%} for HPV 6/11/16/18 infection, approximately 90{\%} for genital warts, approximately 45{\%} for low-grade cytological cervical abnormalities, and approximately 85{\%} for high-grade histologically proven cervical abnormalities have been reported. The full public health potential of HPV vaccination is not yet realized. HPV-related disease remains a significant source of morbidity and mortality in developing and developed nations, underscoring the need for HPV vaccination programs with high population coverage.",
keywords = "Cervical cancer, CIN, Gardasil/Silgard, Genital warts, HPV vaccination",
author = "Garland, {Suzanne M.} and Kjaer, {Susanne K.} and Nubia Mu{\~n}oz and Block, {Stan L.} and Darron Brown and Dinubile, {Mark J.} and Lindsay, {Brianna R.} and Kuter, {Barbara J.} and Gonzalo Perez and Geraldine Dominiak-Felden and Saah, {Alfred J.} and Rosybel Drury and Rituparna Das and Christine Velicer",
year = "2016",
month = "8",
day = "15",
doi = "10.1093/cid/ciw354",
language = "English (US)",
volume = "63",
pages = "519--527",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "4",

}

TY - JOUR

T1 - Impact and effectiveness of the quadrivalent human papillomavirus vaccine

T2 - A systematic review of 10 years of real-world experience

AU - Garland, Suzanne M.

AU - Kjaer, Susanne K.

AU - Muñoz, Nubia

AU - Block, Stan L.

AU - Brown, Darron

AU - Dinubile, Mark J.

AU - Lindsay, Brianna R.

AU - Kuter, Barbara J.

AU - Perez, Gonzalo

AU - Dominiak-Felden, Geraldine

AU - Saah, Alfred J.

AU - Drury, Rosybel

AU - Das, Rituparna

AU - Velicer, Christine

PY - 2016/8/15

Y1 - 2016/8/15

N2 - Prophylactic human papillomavirus (HPV) vaccination programs constitute major public health initiatives worldwide. We assessed the global effect of quadrivalent HPV (4vHPV) vaccination on HPV infection and disease. PubMed and Embase were systematically searched for peer-reviewed articles from January 2007 through February 2016 to identify observational studies reporting the impact or effectiveness of 4vHPV vaccination on infection, anogenital warts, and cervical cancer or precancerous lesions. Over the last decade, the impact of HPV vaccination in real-world settings has become increasingly evident, especially among girls vaccinated before HPV exposure in countries with high vaccine uptake. Maximal reductions of approximately 90% for HPV 6/11/16/18 infection, approximately 90% for genital warts, approximately 45% for low-grade cytological cervical abnormalities, and approximately 85% for high-grade histologically proven cervical abnormalities have been reported. The full public health potential of HPV vaccination is not yet realized. HPV-related disease remains a significant source of morbidity and mortality in developing and developed nations, underscoring the need for HPV vaccination programs with high population coverage.

AB - Prophylactic human papillomavirus (HPV) vaccination programs constitute major public health initiatives worldwide. We assessed the global effect of quadrivalent HPV (4vHPV) vaccination on HPV infection and disease. PubMed and Embase were systematically searched for peer-reviewed articles from January 2007 through February 2016 to identify observational studies reporting the impact or effectiveness of 4vHPV vaccination on infection, anogenital warts, and cervical cancer or precancerous lesions. Over the last decade, the impact of HPV vaccination in real-world settings has become increasingly evident, especially among girls vaccinated before HPV exposure in countries with high vaccine uptake. Maximal reductions of approximately 90% for HPV 6/11/16/18 infection, approximately 90% for genital warts, approximately 45% for low-grade cytological cervical abnormalities, and approximately 85% for high-grade histologically proven cervical abnormalities have been reported. The full public health potential of HPV vaccination is not yet realized. HPV-related disease remains a significant source of morbidity and mortality in developing and developed nations, underscoring the need for HPV vaccination programs with high population coverage.

KW - Cervical cancer

KW - CIN

KW - Gardasil/Silgard

KW - Genital warts

KW - HPV vaccination

UR - http://www.scopus.com/inward/record.url?scp=84982168442&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84982168442&partnerID=8YFLogxK

U2 - 10.1093/cid/ciw354

DO - 10.1093/cid/ciw354

M3 - Review article

VL - 63

SP - 519

EP - 527

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

IS - 4

ER -